LOUISVILLE, CO, October 17, 2006, GlobeImmune, Inc., announced today that the interim results from a placebo-controlled Phase 1b study of GI-5005 in patients chronically infected with hepatitis C virus will be presented at the 57th Annual Meeting of the American … Continue reading
LOUISVILLE, CO, August 28, 2006, GlobeImmune, Inc., today announced that John Frenz Ph.D. has joined the company as Vice President of Operations. Dr. Frenz is responsible for managing all manufacturing operations and process development for GlobeImmune. Dr. Frenz comes to … Continue reading
LOUISVILLE, CO, August 9, 2006, GlobeImmune, Inc., today announced the appointment of Jules Harris M.D. to the GlobeImmune scientific advisory board. Dr. Harris joins existing advisors Teresa Brentnall M.D., Paul Bunn M.D., Dr. Francis Chisari M.D., Charles Dinarello M.D., Edgar … Continue reading
Louisville, CO, June 7, 2006, GlobeImmune, Inc. today announced the initiation of a randomized, placebo-controlled, multi-center Phase 2 clinical trial of GI-4000, GlobeImmune’s therapeutic vaccine for the treatment of patients with early-stage pancreas cancer. The primary goal of the study … Continue reading
Louisville, CO, May 22, 2006 – GlobeImmune today announced that it has been named a winner of the prestigious Red Herring 100 award. GlobeImmune was recognized for its pioneering work on yeast-based products called Tarmogens (Targeted Molecular Immunogens), which activate … Continue reading
GlobeImmune Adds to Executive Management Team LOUISVILLE, CO May 15, 2006GlobeImmune, Inc., today announced that Jeffrey Rona has joined as Chief Business Officer. “Jeff’s extensive experience will add significantly to the senior management team and help us continue to grow … Continue reading
LOUISVILLE, CO, January 10, 2006, GlobeImmune, Inc., today announced the final closing of a Series B Preferred Stock financing. GlobeImmune added an additional $4.1 million to the previously announced first close of $34.3 million, bringing the total amount raised in … Continue reading
LOUISVILLE, CO, December 13, 2005, GlobeImmune, Inc. today announced the relocation of its corporate headquarters to Louisville, Colorado. The new GlobeImmune address is: 1450 Infinite Drive Louisville CO, 80027 The telephone number is: 303-625-2700 The main fax number is: 303-625-2710 … Continue reading
DENVER, CO, September 14, 2005, GlobeImmune, Inc., a biopharmaceutical company developing immunotherapy products called Tarmogens™ for the treatment of cancer and chronic infectious diseases, today announced the initial successful closings of a Series B Preferred Stock financing, raising $34.3 million. … Continue reading
DENVER, CO, August 31, 2005, GlobeImmune, Inc., a biopharmaceutical company that discovers and manufactures immunotherapy products known as Tarmogens™ to treat cancer and infectious disease, today announced the appointment of Carl H. June, M.D. to its Scientific Advisory Board. “We … Continue reading